Glycoprotein News and Research

RSS

SARS-CoV-2 mutations alter dynamics of neutralizing antibodies

A new study describes how monoclonal antibodies raised against SARS-CoV-2 are affected by mutations in the antibody binding site.

20 Aug 2021

SARS-CoV-2 lambda variant escapes immune response via spike mutations

A new study explores the mechanism by which the SARS-CoV-2 lambda variant has acquired immune evasion capabilities above that of the wildtype.

20 Aug 2021

SARS-CoV-2 antibodies found to neutralize bat coronavirus (RaTG13) in new study

A striking new study examines how far antibodies elicited by vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or by natural infection, can neutralize the closely related bat coronavirus (CoV) RaTG13.

19 Aug 2021

How does the SARS-CoV-2 Delta variant’s spike drive membrane fusion and immunity evasion?

A fascinating and timely new study shows how the Delta variant of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) achieved higher transmissibility and resistance to neutralization.

19 Aug 2021

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

In a recently published article in the journal Virologica Sinica, scientists have described the development and validation of a potent nanobody that targets the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV). The nanobody efficiently and specifically blocks the interaction between RBD and angiotensin-converting enzyme 2 (ACE2) and neutralizes the virus.

19 Aug 2021

How delta and kappa variants of SARS-CoV-2 evade the immune system

A new study, available on the bioRxiv* preprint server, describes the neutralizing ability of the monoclonal antibodies against the variants and the difference of the ACE2 binding affinity found in the variants.

17 Aug 2021

Vaccinating previously infected induces more potent antibodies less susceptible to escape from SARS-CoV-2 variants

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causal agent of the coronavirus disease 2019 (COVID-19) pandemic, which has claimed more than 4.3 million lives worldwide. Even after implementing various measures, such as vaccination and social restrictions, SARS-CoV-2 and its variants of concern (VoC) leave the world's public health systems and economies in turmoil.

16 Aug 2021

Moderna COVID-19 vaccine safe and efficacious in adolescents according to a new study

The safety, immunogenicity, and efficacy of the vaccines in adolescents are largely unknown. Now, a new study published in the New England Journal of Medicine evaluates the safety and efficacy of the mRNA-1273 vaccine in adolescents (12-17 years of age).

16 Aug 2021

Research suggests toll-like receptor 4 appears to play role in severe COVID

A group of researchers re-evaluated their previously proposed hypothesis, which stated that the TLR4 activated by the spike glycoprotein S1 domain increases ACE2 expression and, thereby, aids in COVID-19 infection.

16 Aug 2021

Certain intestinal bacteria induce cross-reactive IgA responses to the SARS-CoV-2 spike RBD

A new study finds that human gut bacteria can induce antibodies of the immunoglobulin A (IgA) subtype that cross-react with the SARS-CoV-2 spike RBD.

15 Aug 2021

Study shows efficacy of gamma irradiation of SARS-CoV-2 vaccine candidate in mouse model

A new study reports a more rapid method of viral inactivation in an effort to increase the appeal of inactivated viral vaccines against the COVID-19 pandemic.

10 Aug 2021

Natural vs. vaccine-induced COVID-19 immunity

A new paper discusses the protection offered by immunity against COVID-19 following vaccination as compared to natural infection.

10 Aug 2021

IMBA researchers may have found the "Achilles' heel" of SARS-CoV-2 virus

Researchers identify two sugar-binding proteins that impede the viral entry of circulating SARS-CoV-2 variants.

10 Aug 2021

Research shows how SARS-CoV-2 variants are evolving towards increased furin cleavage efficiency

The spike protein comprises of two subunits: S1 subunit having the receptor-binding domain (RBD) that helps it to bind to the angiotensin-converting enzyme 2 (ACE2), which is present on the cell surface of the host, and the S2 subunit that helps in the fusion of the cellular membrane and the viral membrane.

9 Aug 2021

New insight into impact of SARS-CoV-2 mutations on receptor binding

A recent study by Canadian researchers, currently available on the bioRxiv* preprint server, contributes to the growing body of literature on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by appraising the impact of single mutations on their overall antigenicity and binding affinity for the angiotensin-converting enzyme 2 (ACE2) receptor.

9 Aug 2021

Simplified glycan modeling of the SARS-CoV-2 spike protein

In a research paper recently uploaded to the preprint server bioRxiv* by Gecht et al. (August 4th, 2021), a new method of representing glycan conformers on static protein structures is explored, named GlycoSHIELD.

6 Aug 2021

Multivalent nanobodies show improved neutralization activity against SARS-CoV-2

A state-of-the-art engineering approach toward improving the neutralizing activity of a cross-reactive nanobody, previously generated against the original SARS virus, showed it can be an attractive and viable option against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study is published in the journal Advanced Therapeutics.

5 Aug 2021

Study shows COVID-19 organ-specific outcomes depend on anti-spike glycoprotein antibodies

A recent study from the University of Rochester reveals how the biodistribution kinetics and the affinity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for many different organs in the human body can be affected by antibodies targeting viral spike glycoprotein. The paper is currently available on the bioRxiv* preprint server while it undergoes peer review.

3 Aug 2021

What is the potential of microphysiological systems in COVID-19 research?

In a recently published review article in the journal Drug Discovery Today, scientists have described the utility of human-based microphysiological systems MPSs in understanding the pathophysiology of SARS-CoV-2 infection and developing effective therapeutic interventions. Moreover, they have described the establishment of a global working group to synchronize recent developments around MPSs and COVID-19 research.

3 Aug 2021

Public and private SARS-CoV-2 T cell receptors may be crucial for pan-coronavirus vaccines

Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.

2 Aug 2021

Glycoprotein News and Research

SARS-CoV-2 mutations alter dynamics of neutralizing antibodies

SARS-CoV-2 lambda variant escapes immune response via spike mutations

SARS-CoV-2 antibodies found to neutralize bat coronavirus (RaTG13) in new study

How does the SARS-CoV-2 Delta variant’s spike drive membrane fusion and immunity evasion?

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

How delta and kappa variants of SARS-CoV-2 evade the immune system

Vaccinating previously infected induces more potent antibodies less susceptible to escape from SARS-CoV-2 variants

Moderna COVID-19 vaccine safe and efficacious in adolescents according to a new study

Research suggests toll-like receptor 4 appears to play role in severe COVID

Certain intestinal bacteria induce cross-reactive IgA responses to the SARS-CoV-2 spike RBD

Study shows efficacy of gamma irradiation of SARS-CoV-2 vaccine candidate in mouse model

Natural vs. vaccine-induced COVID-19 immunity

IMBA researchers may have found the "Achilles' heel" of SARS-CoV-2 virus

Research shows how SARS-CoV-2 variants are evolving towards increased furin cleavage efficiency

New insight into impact of SARS-CoV-2 mutations on receptor binding

Simplified glycan modeling of the SARS-CoV-2 spike protein

Multivalent nanobodies show improved neutralization activity against SARS-CoV-2

Study shows COVID-19 organ-specific outcomes depend on anti-spike glycoprotein antibodies

What is the potential of microphysiological systems in COVID-19 research?

Public and private SARS-CoV-2 T cell receptors may be crucial for pan-coronavirus vaccines

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News